Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Titan Pharma (TTNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Titan Pharmaceuticals Prices $9,500,000 Public Offering

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company"), a commercial stage company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM)...

TTNP : 0.22 (-56.00%)
Titan Awarded NIDA Grant For The Development Of A Nalmefene Implant For The Prevention Of Opioid Addiction Relapse

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that it has been awarded a two year grant of approximately $6.7 million from the National Institutes of Health's National Institute on Drug Abuse...

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals: 2Q Earnings Snapshot

SAN FRANCISCO (AP) _ Titan Pharmaceuticals Inc. (TTNP) on Tuesday reported a loss of $869,000 in its second quarter.

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals Reports Second Quarter 2018 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 0.22 (-56.00%)
Titan Announces Amendment To Agreement With Molteni

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has entered into an amendment (the "Amendment") of the previously announced definitive asset purchase, supply and support agreement (the...

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals Provides Update On Parkinson's Disease Clinical Development Program

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals: 1Q Earnings Snapshot

SAN FRANCISCO (AP) _ Titan Pharmaceuticals Inc. (TTNP) on Tuesday reported a loss of $2.6 million in its first quarter.

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals Reports First Quarter 2018 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals To Report First Quarter 2018 Financial Results On May 15, 2018

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / April 2, 2018 / Titan Pharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 2, 2018 at 4:15 PM Eastern Time....

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals reports 4Q loss

SAN FRANCISCO (AP) _ Titan Pharmaceuticals Inc. (TTNP) on Monday reported a loss of $3.7 million in its fourth quarter.

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2017 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 0.22 (-56.00%)
Data Shows That the Global Addiction Treatment Market is Set to Grow

Data provided by Transparency Market Research, indicates that global addiction treatment market was valued at approximately US$ 4.0 billion in 2016 and is anticipated to expand at a CAGR of over 6.0% from...

BICX : 0.1060 (-5.36%)
DRRX : 1.07 (-2.73%)
TTNP : 0.22 (-56.00%)
BDSI : 2.85 (+5.56%)
EGLT : 0.1350 (+50.00%)
Titan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select Territories

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has entered into a definitive asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio...

TTNP : 0.22 (-56.00%)
10-Q: TITAN PHARMACEUTICALS INC

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals reports 3Q loss

SAN FRANCISCO (AP) _ Titan Pharmaceuticals Inc. (TTNP) on Thursday reported a loss of $4.2 million in its third quarter.

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals Reports Third Quarter 2017 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals Schedules Conference Call To Review Third Quarter 2017 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery technology,...

TTNP : 0.22 (-56.00%)
Titan Pharmaceuticals Presents Non-Clinical Data From Liothyronine (L-T3) Implant Studies

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced today the planned presentation of non-clinical data on the use of its ProNeura(TM) subdermal implant for the long-term, sustained delivery of liothyronine...

TTNP : 0.22 (-56.00%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA +0.77
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures closed the Friday session with most contracts 4 to 5 cents in the green. Nearby Dec was up 1.56% over the course of the week. A private export sale this morning was shown for 121,700 MT of 18/19 corn to unknown by the USDA. Total corn ex...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar